Formulation Development
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology With 100% of Treated AML Patients in Complete Remission& Receives FDA Guidance for Registrational Trial of INB-100
IN8bio, Inc. recently announced updated positive clinical data from both of the company’s Phase 1 investigator-sponsored trials of INB-100 for hematological malignancies and INB-200 for…
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for the Treatment of Duchenne Muscular Dystrophy
Wave Life Sciences Ltd. recently announced the US FDA has granted Rare Pediatric Disease Designation to WVE-N531 for the treatment of boys with Duchenne muscular…
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination With Zbtb46 mRNA Delivered With SemaPhore Nanoparticles in Animal Tumor Models
Altamira Therapeutics Ltd. recently announced the publication of a peer-reviewed article in Nature Immunology highlighting the important role of the Zbtb46 gene in the control…
Abzena Supplies Clinical Trial Material for Angiex’s Phase 1 Study of First-in-Class TM4SF1-Directed ADC
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, recently announced that patient dosing has begun for their Phase 1 clinical trial…
ANEW MEDICAL Announces Patents Issued in Major Asian Markets for Use of Genetic Therapy
ANEW MEDICAL, INC. recently announced the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative…
Conduit Pharmaceuticals Enters Exclusive License Agreement With AstraZeneca for Multiple Assets
Conduit Pharmaceuticals Inc. recently announced it has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase…
Apellis & Sobi Announce Positive Topline Results From Phase 3 Study of Pegcetacoplan in C3G & Primary IC-MPGN
Apellis Pharmaceuticals, Inc. recently announced positive topline results from the Phase 3 VALIANT study investigating systemic pegcetacoplan in patients with C3 glomerulopathy (C3G) or primary immune…
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
Palisade Bio, Inc. provided a progress update on the advancement of development for its lead drug candidate, PALI-2108 towards initiation of Phase 1 clinical trials in…
Oragenics Announces Concussion Drug Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics, Inc. recently announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity. ONP-002 is a new…
Nutcracker Therapeutics Announces Publication in ACS Nano Demonstrating the Therapeutic Viability of Nutshell Delivery Vehicles
Nutcracker Therapeutics, Inc. recently announced the publication of its latest peer-reviewed paper, which explores the fundamental aspects of its Nutshell platform of peptoid-based mRNA delivery vehicles.…
Agios to Receive $1.1 Billion in Milestone Payments
Agios Pharmaceuticals, Inc. recently announced it will receive a total of $1.1 billion in milestone payments following US FDA approval of vorasidenib for adult and…
Silo Pharma Announces Partnership With Global CRO for CNS Homing Peptide
Silo Pharma, Inc. recently announced it has entered into an agreement with WuXi AppTec (Hong Kong) Limited for a preclinical small animal study of SPU-16,…
Levicept Announces Positive Results of Phase 2 Trial of Novel Neurotrophin-3 Inhibitor for the Treatment of Patients With Moderate to Severe Osteoarthritis
Levicept Ltd recently announced positive results from its Phase 2 trial of LEVI-04 a novel and first in class neurotrophin-3 (NT-3) inhibitor, showing that LEVI-04…
George Medicines Files NDA for Novel Low Dose Triple Combination for Treatment of Hypertension Following Successful Phase 3 Development Program
George Medicines recently announced its submission to the US FDA of a New Drug Application (NDA) for GMRx2, George Medicines’ lead pipeline candidate for the…
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
Annovis Bio Inc. recently announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1)…
Compass Therapeutics Completes Patient Enrollment in Randomized Study of CTX-009 in Combination With Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Compass Therapeutics, Inc. recently announced it completed enrollment of the planned 150 patients in COMPANION-002, its randomized Phase 2/3 clinical trial of CTX-009 in patients…
New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Clearmind Medicine Inc. recently announced a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating…
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 for Patients Afflicted With Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
NeOnc Technologies Holdings, Inc. has begun patient enrollment for the Phase 2 clinical trial of NEO100-02, the company’s first of two drug candidates proceeding through…
Salubris Biotherapeutics Announces Approval to Initiate Phase 1 Clinical Trial of a 5T4-Targeted ADC in Solid Tumors
Salubris Biotherapeutics, Inc. recently announced it has received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of JK06 in…
FDA Review of PsiGAD2 IND Complete; Clinical Trial for Psilocybin-Assisted Psychotherapy in Patients With Generalized Anxiety Disorder to Proceed
Incannex Healthcare Inc. recently announced it has received approval from the US FDA to conduct its Investigational New Drug (IND) opening Phase 2 clinical trial.…
